Skip main navigation

Home > Search Results

Main contents starts here

Search Results

41 - 60 of about 133

Total 133 documents found.

  •  
  • Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with alpha-GI) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Concomitant therapy with Sulfonylurea) Diabetes mellitus (Concomitant therapy with Biguanide) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn EU Jpn Jpn Jpn Jpn US EU FDA Complete Response Letter (Jun 09) Approved (Apr 10) P-III FDA Complete Response Letter (Sep 09) Filed (Jun 09) P-III Approved (Apr 10) Filed (Jun 09) Filed (Mar 10) Filed (Mar 10) P-III P-III In-house TAK-375 MT1/MT2 receptor agonist (oral) Insomnia Jpn EU Approved (Apr 10) P-III In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-es
  • 1 1 Takeda Pharmaceutical Company Limited Management PolicyManagement Policy Growing Toward aGrowing Toward a ""WorldWorld--Class PharmaceuticalClass Pharmaceutical CompanyCompany"" based on Takedabased on Takeda--ismism President Yasuchika Hasegawa September 28, 2007 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Performance of TakedaPerformance of Takeda 0 200 400 600 800 1,000 1,200 1,400 0 100 200 300 400 500 600 91 92 93 94 95 96 97 98 99 00 01 02 03 04 07(E) Net Sales Operating Income Ordinary Income 05 To achieve consecutive increased income for 17 years 90 06 (Billions of Yen) (Billions of Yen) 2 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Sales of international strategic productsSales of international strategic products * including affiliated companies 0 250 500 2003 2004 2005 '06 184.8 '06 400.7 '06 206.9 '06 337.0 2006 (Billions of Yen) Leuprorelin Lansoprazole Candesartan Pioglitazon 4 Takeda Pharmaceutical Company LimitedTakeda Pharm
  • Takeda Announces New Initiative in Cell Culture-Based Influenza Vaccines August 31, 2010
  • Osaka, Japan, August 31, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has received an official notice from the Pharmaceutical Development Support Center with regard to the granting of a government subsidy for which it had applied. Takeda was notified in writing on July 6 of this decision, and the company has now received the official notice.
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (CONSOLIDATED) Financial Results for the Fiscal Year Ended March 31, 2010 May 12, 2010 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki, Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 25, 2010 Scheduled date of securities report submission: June 25, 2010 Scheduled date of dividend payment commencement: June 28, 2010 (Millions of yen, rounded to the nearest million) 1. Consolidated Results for Fiscal 2009 (April 1, 2009-March 31, 2010) (1) Consolidated Operating Results (Percentage figures represent changes from same period of previous
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company", which was set as a target in the 20062010 Medium-term Plan, the Company has been working on various strategies. To achieve this goal, the Company completed a meaningful acquisition and restructuring last year. Firstly, we evenly separated the value of TAP Pharmaceutical Products Inc. ("TAP")a joint venture between Takeda America Holdings, Inc. ("TAH") and Abbott Laboratories ("Abbott") of the U.S.into two companies in April 2008. As part of this company separation, TAP acquired assets related to the already marketed product Prevacid, as well as those related to TAK-390MR (a drug for gastroesophageal reflux disease) and TMX-67 (a drug for hyperuricemia for patients with chronic gout, discovere
  • ANNUALREPORT2008 Annual Report 2008 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide 1 This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainties, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Takeda has issued an integrated Annual and CSR Report since fiscal 2006, in order to facilitate a comprehensive underst
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 20 - 3. Management Policy (1) Basic Management Policy Focusing on "Takeda-ism" (which refers to integrity = fairness, honesty, and perseverance) as the basis for all its business activities, Takeda is aiming at realizing its management mission of "striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products" through creating new drugs continuously and maximizing the product's potential in the global market as a research-based pharmaceutical company. In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company" as targeted in the 20062010 Medium-term Plan, Takeda created corporate-level, center of excellence R&D, commercial and administrative functions in fiscal 2009, and we will build its organization for global operations. Takeda will dedicate its collective efforts to thoroughly enhance its strengths, such as its "capabilit
  • Amgen, Takeda and Millennium Provide Update on Phase3 Trial of Motesanib in Patients with Non-small Cell Lung Cancer November 20, 2008
  • THOUSAND OAKS, Calif. (Nov. 19, 2008) – Amgen (NASDAQ:AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study’s independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
  • Throughout a history of more than 220 years "creating medicine," Takeda has developed a strong sense of mission and high ethical standards. During this long history, Takeda sees social action programs as an "investment in society," having been addressing various efforts. Based on increasing recognition of "corporate social responsibilities" associated with progress of globalization of society, in 2005, Takeda systematically organized a number of previous activities and placed them into statutory form, such as "Basic Policy on Social Contribution." This policy is shared among the global Takeda group and we have been implementing activities at a global level, centering on four priority areas. Since corporate activities would never be realized without the sustained progress of society, social action programs can be positioned as one of the important company activities. Actually, this concept is nothing new to Japanese, given the long-held philosophy of "Sanpo-yoshi (Where all three parties are happy)." This ter
  • AFFYMAX® AND TAKEDA HONORED WITH THE ALLICENSE 2007 BREATKTHROUGH ALLIANCE AWARD FOR THEIR EXCLUSIVE GLOBAL AGREEMENT FOR HEMATIDE™ April 18, 2007
  • PALO ALTO, Calif., and OSAKA, Japan, April 18, 2007 - Affymax, Inc. (Nasdaq: AFFY), a biopharmaceutical company, and Takeda Pharmaceutical Company Limited today announced that they were honored with the Allicense 2007 Breakthrough Alliance Award for their exclusive global agreement to develop and commercialize Hematide™, Affymax's lead product candidate, for the treatment of anemia. The award, given for the best and most innovative practices in drafting and negotiating alliances between biotechnology and pharmaceutical companies, is sponsored by Recombinant Capital and was presented at the Allicense 2007 conference in San Francisco.
  • Takeda to Acquire Paradigm Therapeutics March 12, 2007
  • OSAKA, JAPAN and CAMBRIDGE UK March 12, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and Paradigm Therapeutics Limited ("Paradigm") agreed on March 12, 2007 to the acquisition of Paradigm by Takeda. Paradigm shareholders were advised by Avlar BioVentures Limited. Financial terms were not disclosed. Subject to completion, which is expected to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings B.V., a wholly owned subsidiary of Takeda. Additionally, Paradigm will be renamed Takeda Cambridge Limited, and Paradigm's subsidiary in Singapore will be renamed Takeda Singapore Pte Limited.
  • SocietyRelationship with Consistently and sincerely promoting the establishment of a relationship with society, Takeda globally develops a broad range of initiatives. Takeda Annual Report 200638 TPNA employees participating in the "Walk for Charity" Contribution to Society: Four Priority Areas 1. The area directly related to the Management Mission: "We strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products" 2. The area concerning "The aim to live an affluent life with body and mind in good health," as well as "eliminating any obstacles to such a goal" based on the Management Mission 3. Contributions toward developing a bright and dream-inspiring future 4. The projects to be inherited and further developing the accumulated expertise that was previously converted into tangible form by our fore fathers, based on Takedaism IN JAPAN The area directly related to the Management Mission: "We strive toward better health for individuals and progress in medic
  • New Data Shows Takeda's Actos® (pioglitazone HCl) Reduced Heart Attacks by 28 Percent in People with Type 2 Diabetes
    PROactive Study also showed a 37 percent reduction in acute coronary syndrome with ACTOS November 17, 2005
  • Dallas, TX, November 16, 2005 − New results from secondary analyses of the landmark PROactive Study found that ACTOS® (pioglitazone HCl) significantly reduced the occurrence of fatal and non−fatal heart attacks and acute coronary syndrome (ACS) in high−risk patients with type 2 diabetes who had a previous heart attack. Importantly, these results were above and beyond those seen with standard of care treatment. The findings, which were revealed today at the American Heart Association's Scientific Sessions 2005, build on previously−reported results from the PROactive Study, showing that ACTOS, an oral antidiabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16 percent in high−risk patients with type 2 diabetes. "Takeda is breaking new ground with the PROactive Study. Never before have this many high−risk people with type 2 diabetes and cardiovascular disease been studied," said Robert Spanheimer, M.D., medical director for diabetes and metabolism at Takeda Pharmaceuticals North America. "Through this innovative research, we now know that ACTOS can markedly reduce the recurrence of heart attacks." These data assessed the effects of ACTOS on cardiovascular morbidity and mortality in 2,445 high−risk patients who had previously had a heart attack, a population that tends to have a very poor prognosis. The results show that in patients taking ACTOS on top of standard of care treatment:
  • ACTOplus met™ (pioglitazone HCl and metformin HCl) Now Available in U.S. Pharmacies
    New product combines two widely used diabetes medications in a single tablet, offering patients a convenient option November 1, 2005
  • LINCOLNSHIRE, Ill., November 1, 2005 −Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met™(pioglitazone HCl and metformin HCl) is now available by prescription in pharmacies across the United States for the treatment of type 2 diabetes. This is the second Takeda product launch in the United States this year, following the approval of ROZEREM™ (ramelteon) on July 22, 2005.ACTOplus met™ combines ACTOS®(pioglitazone HCl) and metformin, two widely used diabetes medications, in a single tablet. ACTOS directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels. "Takeda is pleased to provide ACTOplus met, an important addition to the ACTOS family of products," said Mark Booth, president of Takeda. "Since most people with type 2 diabetes take multiple therapies to reach their target glucose levels, we believe that this combination pill will offer an effective, convenient new treatment option for patients."To offer physicians greater flexibility in treating their patients' needs, ACTOplus met will be available in two dosages of pioglitazone/metformin − 15 mg/500 mg and 15 mg/850 mg − both of which are to be given once a day or in divided doses not exceeding the maximum recommended daily doses of pioglitazone 45 mg and metformin 2,550 mg, according to the approved labeling.According to the American Diabetes Association, diabetes affects more than 18 million people, and type 2 diabetes is the most common form of the disease. Both ACTOS and metformin are widely used medications in the treatment of type 2 diabetes and both have a known safety profile. Combining these medications may provide patients with an easier way to take the two drugs, as they are already often prescribed together to help manage the disease.
  • Takeda Acquires the Rights to DPP4 Inhibitors Granted to PPD July 14, 2005
  • Osaka, Japan/Wilmington, N.C., July 14(JST) and 13(ET), 2005 --- Takeda Pharma-ceutical Company Limited ("Takeda") and PPD, Inc. (Nasdaq: PPDI) today announced an agreement in which Takeda acquired the development and marketing rights to all dipeptidyl peptidase IV (DPP4) inhibitors previously granted to PPD under an agreement between PPD and Syrrx, Inc. Takeda acquired Syrrx, Inc., now known as Takeda San Diego, Inc., in March 2005.
  • 1 Takeda Pharmaceutical Company Limited Our pipelineOur pipeline Kazuaki Ikeya Corporate Officer, General Manager Strategic Product Planning Dept. MM PP DD RR AA PP 2 Takeda Pharmaceutical Company Limited Focused Therapeutic AreasFocused Therapeutic Areas Franchise I: Life style-related diseases Franchise II :Oncology & Urologic diseases Franchise III:Central nervous system diseases Franchise IV:Gastroenterology diseases LCM LCM : Life Cycle Management 3 Takeda Pharmaceutical Company Limited Franchise I: Life styleFranchise I: Life style--related disease(1)related disease(1) ○High dose(Jpn)TCV-116 ○Hyperlipidemia (U.S.,EU)TAK-475 〇Chronic heart failure(U.S.)TCV-116 ○Chronic heart failure(EU)TCV-116 ○ Fixed Combination drug of ACTOS/Metformin (U.S.) AD-4833MET ○ Fixed Combination drug of ACTOS/Metformin (EU) AD-4833MET ○ Fixed combination with diuretic (Jpn) TCV-116 ○Chronic heart failure(Jpn)TCV-116 ○Diabetic Retinopathy(EU)TCV-116 DIRECT ApprovalNDAPhIIIPhIIIndications/formulationsProjects Second h

Pages:[1] [2] [3] [4] [5] [6] [7]   Next

Page Top